4,7-Dimethoxy-1,10-Phenanthroline: An Excellent Ligand for the Cu-Catalyzed *N*-Arylation of Imidazoles

Ryan A. Altman and Stephen L. Buchwald*

Department of Chemistry Massachusetts Institute of Technology Cambridge, MA 02139

sbuchwal@mit.edu

Supporting Information

Table of Contents:

General Considerations	S2
Synthesis of 4,7-dimethoxy-1,10-phenanthroline	S 3
Experimental procedures for the N-arylation of imidazole with aryl iodides	S7
Experimental procedures for the N-arylation of imidazole with aryl bromides	S13
NMR Data	S 18
References	S32

General Considerations.


All reactions were carried out in resealable test tubes with teflon septa and run under a dry argon or nitrogen atmosphere. Copper (I) oxide (97%) was purchased from Aldrich company as a red powder. Anhydrous Cs₂CO₃ (99.9%) was purchased from Alfa Aesar; the bulk of the material was stored under nitrogen in a Vacuum Atmospheres glovebox. Small portions (~5 g) were removed from the glovebox in glass vials, stored in the air in a desiccator filled with anhydrous calcium sulfate, and weighed in the air. Poly(ethylene glycol) (M_n 3,400) was purchased from Aldrich. Generally, aryl halides and imidazoles were purchased from commercial sources and used without further purification. When necessary, aryl halides were filtered through neutral alumina, or distilled. Butyronitrile (\geq 99 %) was purchased from Aldrich in Sure-Seal ® bottles. Flash column chromatography was performed with EM Science silica gel 60 (230-400 mesh). In all cases, dichloromethane was used to transfer the crude reaction material onto a silica gel column. A gradient elution technique was used for column chromatography, beginning with hexane and continuing to the specified concentration of ethyl acetate in hexane.


Yields reported in the publication are isolated (except where noted) and represent an average of at least two independent runs. Yields reported in the supporting information refer to a single experiment. Compounds described in the literature were characterized by comparing their ¹H NMR, and melting point (m.p.) to the previously reported data; their purity was confirmed by gas chromatographic analyses (GC). For known compounds prepared using the new method (conditions) described, a copy of the ¹H NMR spectrum, of each, is included. GC analyses were

performed on a Hewlett Packard 6890 instrument with an FID detector and a Hewlett Packard 10 m x 0.2 mm i.d. HP-1 capillary column using dodecane as an internal standard. Previously unknown compounds were synthesized, purified and analyzed from a single run and were then repeated to determine an average yield. They were characterized by ¹H NMR, ¹³C NMR, m.p., and elemental analysis. Elemental analyses were performed by Atlantic Microlabs, Inc., Norcross, GA. For those compounds that did not give a satisfactory elemental analysis, a copy of their ¹H NMR spectrum is included. ¹H NMR and ¹³C NMR were recorded on Varian 300 MHz and 500 MHz instruments with chemical shifts reported relative to the deuterated solvent or TMS. IR spectra were recorded on a Perkin-Elmer System 2000 FT-IR instrument for all previously unknown compounds (KBr disc). Melting points (uncorrected) were obtained on a Mel-Temp II capillary melting point apparatus.

Synthesis of 4,7-dimethoxy-1,10-phenanthroline (L).

The synthesis of \mathbf{L} was adapted from literature precedent.¹ A larger scale preparation of \mathbf{L} can be preformed as follows. Alternatively, $\mathbf{2}$ can be purchased in gram quantities from commercial sources.





1,2-Bis-[(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidenemethyl)amino]benzene (1).

An oven-dried 2 L 2-neck flask equipped with a mechanical stirrer was charged with trimethyl orthoformate (850 mL, 7.8 mol) and Meldrum's acid (101 g, 0.700 mmol). The flask was fitted with a reflux condenser; the contents were flushed with N₂ and brought to a gentle reflux for 2 h. The resulting red solution was cooled (~ 80 °C) and phenylene diamine (32.4 g, 300 mmol) was added portionwise (*exothermic reaction*) resulting in the formation of a yellow solid. The mixture was heated to reflux, stirred vigorously for an additional hour and then cooled to room temperature. The resulting solid was filtered, washed with cold acetone (slightly soluble) and dried to afforded 95 g (77%) of product as a flaky light-yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ 11.34 (br d, 2H), 8.50 (d, 2H), 7.41 (m, 4H, all ArH), 1.74 (s, 12H, Me). m.p. 208-210, decomp. (Lit. 209, decomp.).^{3a}

4,7-Dihydroxy-1,10-phenanthroline (2). A 5 L 3-neck flask equipped with a mechanical stirrer and a *large air-cooled* reflux condensor was charged with 3 L of diphenyl ether and was heated to 240 °C using a heating mantle. During the addition of **1**, the flask was open to atmospheric

pressure under a stream of N₂. Precursor **1** was added in small portions resulting in vigorous gas evolution (*Caution*). When the addition was complete, the mixture was brought to reflux (260 \cdot C) for 30 min. The mixture was allowed to cool to 80 \cdot C, and the precipitate was isolated by vacuum filtration and washed with acetone until the filtrate was colorless. The product was further washed with excess hexane and diethyl ether. Drying by vacuum filtration, then under hi-vac at 60 \cdot C, afforded 41.5 g (86%) of a fine dark-brown powder. Although the title compound was essentially insoluble in common NMR solvents, a spectrum could be obtained using NaOH in D₂O. ¹H NMR (D₂O, NaOH, 400 MHz) δ 8.17 (d, 2H, *J* = 5.6 Hz), 7.75 (s, 2H), 6.43 (d, 2H *J* = 5.6 Hz). Anal Calc. for C₁₂H₈N₂: C 67.92, H 3.80. Found: C 67.60, H 3.59. m.p. stable up to 250 °C (Lit. 471-474, decomp.).²

4,7-Dichloro-1,10-phenanthroline (3). A 1 L 2-neck round bottom flask equipped with a stir bar, reflux condenser, and distillation apparatus was flame-dried and allowed to cool under an atmosphere of N₂. Phosphorous oxychloride (400 mL) and **2** (20.0 g, 94.3 mmol) were added to the flask under a N₂ purge. The apparatus was immersed in an oil bath and heated at reflux for 2 h (the condenser for the distillation apparatus was not filled with water at this time). After this period, the circulation of water for the distillation apparatus was turned on and roughly half of the excess phosphorous oxychloride was removed by gentle vacuum distillation. The solution was cooled to room temperature and crushed ice was slowly added to the reaction mixture (*Caution: very exothermic!*) while keeping the temperature between 10 and 30 °C with an ice bath. When HCl gas evolution ceased, the acidic solution was stirred for one hour at room temperature to dissolve the black solids that formed. The resulting dark cloudy solution was filtered through activated charcoal (Darco®) to give a translucent-beige solution, which was


brought to pH 13 by the slow addition of 20% KOH solution while maintaining the temperature below 25 °C. The white precipitate that formed was collected by suction filtration, washed with excess H₂O, and dried under vacuum overnight at 60 °C affording **3** as a white solid. The product was used in the subsequent step without further purification. ¹H NMR (DMSO, 400 MHz) δ 9.09 (d, 2H, *J* = 4.8 Hz), 8.41 (s, 2H), 8.08 (d, 2H, *J* = 4.8 Hz). m.p. 245-247 (Lit. 249-250).^{3c}

4,7-Dimethoxy-1,10-phenanthroline (L). An oven-dried 3-neck round bottom flask was cooled under a stream of nitrogen. Anhydrous methanol (1.2 L) was added, and purged with N₂ for 10 min. Sodium metal (9.20 g, 400 mmol) was slowly added in small pieces while the solution was stirred. A reflux condenser was attached, and **3** (all that was produced in the previous step) was added. The flask was heated to reflux for 24 hours under an atmosphere of N₂. Concentration of the resulting solution to ~30 mL and addition of cold water (250 mL) resulted in the precipitation of a tan solid. The flask was stored overnight in a refrigerator to allow complete precipitation of the solid. The product was collected by filtration, washed with excess water, and dried under vacuum overnight at 60 °C affording 16.7 g (74 % over 2 steps) of a tan solid, which can be recrystallized from benzene. ¹H NMR (CDCl₃, 300 MHz) δ 8.93 (d, 2H, *J* = 5.3 Hz), 8.18 (s, 2H), 7.03 (d, 2H, *J* = 5.3 Hz), 4.09 (s, 6H). m.p. 210-212 (Lit. 209-210).^{3e}

General procedure for the *N*-arylation of imidazoles with aryl iodides.


An oven-dried screw-cap test tube was charged with Cu_2O (0.025 mmol), L (0.075 mmol), imidazole (1.2 mmol), aryl iodide (1.00 mmol, if solid), poly(ethylene glycol) (200 mg), Cs_2CO_3 (1.4 mmol), and a magnetic stir bar. The reaction vessel was fitted with a rubber septum. The vessel was evacuated and back-filled with argon or nitrogen, and this sequence was repeated an additional time. Aryl iodide (1.00 mmol, if liquid) and solvent (0.5 mL) were then added successively. The reaction tube was sealed, and stirred in a pre-heated oil bath for the designated time period. The reaction mixture was cooled to room temperature, diluted with dichloromethane (10 mL), and filtered through a plug of celite, eluting with additional dichloromethane (50 mL). The filtrate was concentrated and the resulting residue was purified by flash chromatography to provide the desired product.

Experimental procedures for the *N*-arylation of imidazole with aryl iodides.




1-Phenyl-1*H*-imidazole

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), iodobenzene (112 μ L, 1.00 mmol), and imidazole (82 mg, 1.2 mmol), with NMP (0.5 mL) as solvent for 3 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) afforded 1-phenyl-1*H*-imidazole (slightly yellow oil, 131 mg, 92 %). The low catalyst loading experiment was preformed using the general procedure with Cu₂O (0.4 mg, 0.0025 mmol), **L** (1.8 mg, 0.0075 mmol), PEG (2.0 g), Cs₂CO₃ (4.50 g, 14 mmol), iodobenzene (1.12 mL, 10 mmol), and imidazole (820 mg, 12 mmol), in butyronitrile (2.0 mL) as solvent for 48 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) provided 1-phenyl-1*H*-imidazole (slightly yellow oil, 1.34 g, 93 %). ¹H NMR (300 MHz, CDCl₃) δ 7.82 (s, 1H), 7.47-7.41 (m, 2H), 7.36-7.29 (m, 3H), 7.25 (bs, 1H), 7.18 (bs, 1H).³ A copy of the ¹H NMR spectrum is provided.




3-Imidazol-1-yl-benzonitrile

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 3-iodobenzonitrile (229 mg, 1.00 mmol), and imidazole (82 mg, 1.2 mmol), with butyronitrile (0.5 mL) as solvent for 24 h at 90 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) 3-imidazol-1-yl-benzonitrile (white needles, 158 mg, 94 %). ¹H NMR (500 MHz, CDCl₃) δ 7.89 (s, 1H), 7.71-7.60 (m, 4H), 7.30 (bs, 1H), 7.25 (bs, 1H). m.p. 151-154 °C (Lit. 156-157 °C).⁴ A copy of the ¹H NMR spectrum is provided.




1-(3-Nitro-phenyl)-1*H*-imidazole

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 3-nitroiodobenzene (249 mg, 1.00 mmol), and imidazole (83 mg, 1.2 mmol) with acetonitrile (0.5 mL) as solvent for 29 h at 80 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) 1-(3-nitro-phenyl)-1*H*-imidazole (white solid, 177 mg, 93 %). ¹H NMR (500 MHz, CDCl3) δ 8.25 (t, 1H, *J* = 1.9), 8.19 (ddd, 1H, *J* = 1.1, 1.9, 7.9 Hz), 7.94 (s, 1H), 7.75 (ddd, 1H, *J* = 1.4, 2.2, 8.1 Hz), 7.69 (t, 1H, *J* = 8.0 Hz), 7.36 (s, 1H), 7.23 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 149.1, 138.3, 125.5, 131.5, 131.2, 126.9, 122.1, 118.0, 116.2. m.p. 109-110 °C (Lit. 109-110 °C).⁵ A copy of the ¹H NMR spectrum is provided.




4-Imidazol-1-yl-benzoic acid ethyl ester

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), ethyl-4-iodobenzoate (168 μ L, 1.00 mmol), and imidazole (82 mg, 1.2 mmol), 3 Å molecular sieves (200 mg, powdered, flame activated) with acetonitrile (0.5 mL) as solvent for 23 h at 80 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) 4-imidazol-1-yl-benzoic acid ethyl ester (white crystals, 184 mg, 84 %). ¹H NMR (500 MHz, CDCl₃) δ 8.18 (td, 2H, *J* = 1.8, 8.5 Hz), 7.96 (s, 1H), 7.48 (td, 2H, *J* = 1.8, 8.8), 7.37 (s, 1H), 7.26 (s, 1H), 4.43 (q, 2H, *J* = 7.1 Hz), 1.44 (t, 3H, *J* = 7.0 Hz). m.p. 101-103 °C (Lit. 100-102 °C).⁶ A copy of the ¹H NMR spectrum is provided.




1-(4-Bromo-phenyl)-1*H*-imidazole⁷

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 1-bromo-4-iodobenzene (340 mg, 1.20 mmol), and imidazole (68 mg, 1.0 mmol) with butyronitrile (0.5 mL) as solvent for 24 h at 90 °C. Chromatographic purification (hexane / ethyl acetate 1 : 1) provided 1-(4-bromo-phenyl)-1*H*-imidazole (white crystals, 171 mg, 78 %). ¹H NMR (300 MHz, CDCl₃) δ 7.83 (bs, 1H), 7.63 (m, 2H), 7.32-7.20 (m, 4H). m.p. 120-122 °C. GC/MS of the crude material showed an 6.1 : 1 mixture of 1-(4-bromo-phenyl)-1*H*-imidazole to 1-(4-iodo-phenyl)-1*H*-imidazole. A copy of the ¹H NMR spectrum is provided.




1-(3,5-Dichloro-phenyl)-2-methyl-1*H*-imidazole

The general procedure was followed using Cu₂O (7.2 mg, 0.05 mmol), L (36 mg, 0.15 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 1,3-dichloro-5-iodobenzene (273 mg, 1.00 mmol), 2-methylimidazole (100 mg, 1.2 mmol) with butyronitrile (0.5 mL) as solvent for 24 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) provided 1-(3,5-dichloro-phenyl)-2-methyl-1*H*-imidazole (white needles, 194 mg, 86 %). ¹H NMR (300 MHz, CDCl₃) δ 7.44 (t, 1H, J = 1.8), 7.23 (d, 2H, J = 1.9), 7.05 (d, 1H, J = 1.2), 6.99, (d, 1H, J = 1.2), 2.40 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 139.8, 135.8, 128.5, 128.4, 124.1, 14.0. IR (KBr disc, cm⁻¹) 1534, 1501, 1463, 1451, 1405, 1305, 1176, 1143, 1115, 1099, 985, 850, 781. Anal. Calc. for C₁₀H₈N₂Cl₂: C 52.89, H 3.55. Found: C 52.95, H 3.44. m.p. 122-125 °C.




1-(2-Isopropyl-phenyl)-1*H*-imidazole

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 2-isopropyl iodobenzene (246 mg, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.5 mL) as solvent for 48 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 1) provided 1-(2-isopropyl-phenyl)-1*H*-imidazole (white crystals, 171 mg, 92 %). ¹H NMR (300 MHz, CDCl₃) δ 7.57 (bs, 1H), 7.46-7.42 (m, 2H), 7.31-7.11 (m, 3H), 7.05 (m, bs), 2.74 (heptet, 1H, *J* = 6.9 Hz), 1.16 (d, 6H, *J* = 6.9 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 145.0, 135.1, 129.4, 129.2, 127.0, 126.7, 126.4, 121.1, 27.4, 24.0. m.p. 76-77 °C (Lit. 67-68 °C).⁸ Anal. Calc. for C₁₂H₁₄N₂: C 77.38, H 7.58. Found: C 77.42, H 7.78. A copy of the ¹H NMR spectrum is provided.




(2-Imidazol-1-yl-phenyl)-methanol

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 2-iodobenzylalcohol (234 mg, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.3 mL) as solvent for 24 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 1) provided (2-imidazol-1-yl-phenyl)-methanol (clear crystals, 165 mg, 95 %). ¹H NMR (300 MHz, CDCl₃) δ 7.62 (dd, 2H, *J* = 1.7, 7.6 Hz), 7.45 (td, 1H, *J* = 1.4, 7.5 Hz), 7.38 (td, 1H, *J* = 1.4, 7.4 Hz), 7.23 (dd, 1H, *J* = 1.1, 7.7 Hz), 7.13 (s, 1H), 7.08 (s, 1H), 4.90 (bs, 1H), 4.46 (s, 1H). m.p. 102-104 °C (Lit. 100.5-102.5 °C). ⁹ A copy of the ¹H NMR spectrum is provided.




1-Biphenyl-2-yl-1*H*-imidazole

The general procedure was followed using Cu₂O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 2-iodobiphenyl (176 μ L, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.6 mL) as solvent for 72 h at 120 °C. Chromatographic purification (hexane / ethyl acetate 1 : 1) provided 1-biphenyl-2-yl-1*H*-imidazole (slighly yellow crystals, 179 mg, 81 %). ¹H NMR (300 MHz, CDCl₃) δ 7.50-7.33 (m, 5H), 7.30-7.24 (m, 3H), 7.02 (bs, 1H), 6.82 (bs, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 137.8, 137.5, 135.2, 131.5, 128.7, 128.7, 128.6, 128.3, 127.8, 126.3. Anal. Calc. for C₁₅H₁₂N₂: C 81.79, H 5.49. Found: C 81.50, H 5.46. m.p. 93-95 °C.



1-Naphthalen-1-yl-1*H*-imidazole

The general procedure was followed using Cu₂O (7.2 mg, 0.05 mmol), L (36 mg, 0.15 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 1-iodonaphthalene (146 μ L, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with NMP (0.3 mL) as solvent for 24 h at 110 °C. The crude reaction mixture was dissolved in 20 mL of water, and extracted with dichloromethane (5 x 30 mL). The combined organic layers were dried with MgSO₄, and the solvent was removed *in vacuo*. Chromatographic purification (hexane / ethyl acetate 1 : 1) provided 1-naphthalen-1-yl-1*H*-imidazole (yellow-white solid, 179 mg, 92 %). ¹H NMR (300 MHz, CDCl₃) δ 7.94-7.92 (m, 2H), 7.76, (bs, 1H), 7.61-7.48 (m, 4 H), 7.43 (d, 1H, *J* = 7.0 Hz), 7.30 (bs, 1H), 7.25 (bs, 1H). m.p. 63-64 °C (Lit. 62 °C).¹⁰ A copy of the ¹H NMR spectrum is provided.



1-(4-Fluoro-phenyl)-2-phenyl-1*H*-imidazole

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 4-fluoroiodobenzene (222 mg, 1.00 mmol), 2-phenylimidazole (173 mg, 1.2 mmol) with butyronitrile (0.3 mL) as solvent for 24 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 3 : 1) provided 1-(4-fluoro-phenyl)-2-phenyl-1*H*-imidazole (white solid, 211 mg, 89 %). ¹H NMR (300 MHz, CDCl₃) δ 7.36-7.30 (m, 2H), 7.24-7.16 (m, 4H), 7.15-7.09 (m, 2H), 7.06 (s, 1H), 7.03-6.96 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 163.5, 160.2, 134.5, 129.0, 128.5, 128.4, 128.2, 127.6, 127.5, 116.5, 116.2. IR (KBr disc, cm⁻¹) 1509, 1501, 1466, 1414, 1303, 1285, 1233, 1212, 1151, 1128, 1091, 1068, 970, 915, 840, 775,

747, 715, 697. Anal. Calc. for C₁₅H₁₁N₂F: C 75.62, H 4.65. Found: C 75.39, H 4.62. m.p. 111-114 °C.

General procedure for the *N*-arylation of imidazoles with aryl bromides.


An oven-dried screw-cap test tube was charged with Cu_2O (0.05 mmol), L (0.15 mmol), imidazole (1.2 mmol), aryl bromide (1.00 mmol, if solid), poly(ethylene glycol) (200 mg), Cs_2CO_3 (1.4 mmol), and a magnetic stir bar. The reaction vessel was fitted with a rubber septum. The vessel was evacuated and back-filled with argon or nitrogen, and this sequence was repeated an additional time. Aryl bromide (1.00 mmol, if liquid), and solvent (0.5 mL) were then added successively. The reaction tube was sealed, immersed, and stirred in a preheated oil bath for the designated time period. The reaction mixture was cooled to room temperature, diluted with dichloromethane (10 mL), filtered through a plug of celite, and eluted with additional dichloromethane (50 mL). The filtrate was concentrated and the resulting residue was purified by flash chromatography to provide the desired product.

Experimental procedures for the *N*-arylation of imidazole with aryl bromides.

4-Imidazol-1-yl-phenol


The general procedure was followed using Cu₂O (7.2 mg, 0. 05 mmol), L (36 mg, 0.15 mmol), PEG (400 mg), Cs₂CO₃ (1.0 g, 3.0 mmol), 4-bromophenol (172 mg, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.5 mL) as solvent for 15 h at 110 °C. After cooling to ambient temperature, the crude reaction mixture was dissolved in 20 mL 2M $HCl_{(aq)}$, and washed once with diethyl ether. The aqueous layer was brought to pH 8 with Na₂CO₃, and extracted repeatedly with CH₂Cl₂. The combined organic layers were dried with anhydrous MgSO₄, and concentrated.

Chromatographic purification (1 % ethanol in ethyl acetate, dry pack) afforded 4-imidazol-1-ylphenol (white crystals, 198 mg, 90 %). ¹H NMR (300 MHz, CD₃OD) δ 7.95 (bs, 1H), 7.41 (bs, 1H), 7.35-7.30 (m, 2H), 7.01 (bs, 1H), 6.92-6.87 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.7, 130.8, 129.8, 124.3, 117.4, 24.0. m.p. 196-198 °C (Lit. 188-190°C [203-205 °C MeOH, H₂O]).¹¹ A copy of the ¹H NMR spectrum is provided.



3-Imidazol-1-yl-phenylamine


The general procedure was followed using Cu₂O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 3-bromoaniline (109 μ L, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.25 mL) as solvent for 20 h at 110 °C. Chromatographic purification (ethyl acetate) afforded 3-imidazol-1-yl-phenylamine (white powder, 141 mg, 88 %). ¹H NMR (300 MHz, CDCl₃) δ 7.79 (bs, 1H), 7.21-7.15 (m, 3H), 6.72-6.68 (m, 1H), 6.64-6.60 (m, 2H). 4.01 (bs, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 148.2, 138.4, 135.6, 130.7, 130.1, 118.4, 114.0, 111.1, 107.7. m.p. 112-114 °C (Lit. 111-113 °C).¹² A copy of the ¹H NMR spectrum is provided.



1-(4-Imidazol-1-yl-phenyl)-ethanone


The general procedure was followed using Cu₂O (7.2 mg, 0.05 mmol), L (36 mg, 0.15 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 4-bromoacetophenone (199 mg, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.4 mL) as solvent for 48 h at 110 $^{\circ}$ C. Chromatographic

purification (hexane / ethyl acetate 1 : 3) afforded 1-(4-imidazol-1-yl-phenyl)-ethanone (white solid, 159 mg, 86 %). ¹H NMR (300 MHz, CDCl₃) δ 8.04, (m, 2H), 7.92 (bs, 1H), 7.46 (m, 2H), 7.33 (bs, 1H), 7.19 (bs, 1H), 2.59 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 196.6, 140.7, 135.7, 135.4, 131.2, 130.4, 120.7, 117.8, 26.7. m.p. 112-114 °C (Lit. 110-112 °C).¹³ A copy of the ¹H NMR spectrum is provided.



1,4-*bis*(Imidazol-1-yl)-benzene¹⁴

The general procedure was followed using Cu₂O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), Cs_2CO_3 (0.90 g, 2.8 mmol), 1,4-dibromobenzene (236 mg, 1.00 mmol), and imidazole (164 mg, 2.4 mmol) with NMP (0.5 mL) as solvent for 30 h at 110 °C. The crude reaction mixture was diluted in excess CH_2Cl_2 , and filtered through a celite plug. After removal of the solvent *in vacuo*, the product was crystallized from EtOAc and stored in a freezer overnight, to afford 1,4-*bis*(imidazol-1-yl)-benzene (white solid, 200 mg, 95 %). ¹H NMR (500 MHz, CDCl₃) δ 7.90 (bs, 2H), 7.54 (s, 4H), 7.32 (bs, 1H), 7.26 (bs, 1H). m.p. 190 °C (decomp.). IR (KBr disc, cm⁻¹) 1534, 1485, 1304, 1248, 1105, 1059. Anal Calc. for $C_{12}H_{10}N_4$: C 68.56, H 4.79. Found C 68.49, H 4.90.




1,2-Diphenyl-1*H*-imidazole

The general procedure was followed using Cu₂O (14.4 mg, 0.10 mmol), **L** (72 mg, 0.30 mmol), PEG (200 mg), Cs_2CO_3 (0.45 g, 1.4 mmol), 4-t-butylbromobenzene (173 µL, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.6 mL) as solvent for 72 h at 120 °C.

Chromatographic purification (hexane / ethyl acetate 1 : 1) afforded 1,2-diphenyl-1*H*-imidazole (white crystals, 198 mg, 90 %). ¹H NMR (300 MHz, CDCl₃) δ 7.42-7.32 (m, 5H), 7.28-7.16 (m, 6H), 7.14 (d, 1H, *J* = 1.1 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 138.6, 130.4, 129.5, 129.1, 128.6, 128.4, 128.2, 128.2, 125.9, 123.0. m.p. 88-89 °C (Lit. 90 °C).¹⁵ A copy of the ¹H NMR spectrum is provided.

1-(4-tert-Butyl-phenyl)-2-methyl-1H-imidazole


The general procedure was followed using Cu₂O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 4-t-butylbromobenzene (173 μ L, 1.00 mmol), 2-methylimidazole (100 mg, 1.2 mmol) with butyronitrile (0.25 mL) as solvent for 48 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) afforded 1-(4-*tert*-butyl-phenyl)-2-methyl-1*H*-imidazole (yellow oil, 207 mg, 97 %). ¹H NMR (300 MHz, CDCl₃) δ 7.41 (m, 2H), 7.12 (m, 1H), 6.94 (bs, 1H), 6.91 (bs, 1H), 2.28 (s, 3H), 1.29 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 151.1, 135.3, 127.5, 126.3, 124.9, 12.7, 34.6, 31.3, 13.8. IR (KBr Disc, cm ⁻¹) 2962, 2870, 1608, 1579, 1513, 1463, 1419, 1365, 1302, 1269, 1178, 1139, 1114, 996, 986, 842, 730, 674, 571. A copy of the ¹H NMR spectrum is provided.





1-ortho-Tolyl-1H-imidazole


The general procedure was followed using Cu₂O (7.2 mg, 0.05 mmol), L (36 mg, 0.15 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 2-bromotoluene (120 μ L, 1.00 mmol), and imidazole (82


mg, 1.2 mmol) with butyronitrile (0.3 mL) as solvent for 28 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 1) afforded 1-*ortho*-tolyl-1*H*-imidazole (yellow oil, 140 mg, 89 %). ¹H NMR (300 MHz, CDCl₃) δ 7.59 (bs, 1H), 7.37-7.28 (m, 3H), 7.23-7.20 (m, 2H), 7.06 (bs, 1H), 2.19 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 148.2, 138.4, 135.6, 130.7, 130.1, 118.4, 114.0, 111.1, 107.7.¹⁶ A copy of the ¹H NMR spectrum is provided.
























S25











S29



S30



¹ The synthesis of **1**, **2**, **3** and **L** were performed according to a combination of the following procedures. (a) Graf, I. G.; Jastreiter, D.; da Silva, L. E.; Rebelo, R. A.; Montalban, A. G.; McKillop, A. *Tetrahedron* **2002**, *58*, 9095. (b) Schmittel, M.; Ammon, H. *Eur. J. Org. Chem.* **1998**, 785. (c) Snyder, H. R.; Freier, H. E. *J. Am. Chem. Soc.* **1946**, *68*, 1320. d) Wehman, P.; Kaasjager, de Lange, W. G.; Jartl, F.; Kamer, P. C. J.; van Leeuwen, P. W. N. M.

Organometallics **1995**, *14*, 3751. (e) Zacharias, D. E.; Case, F. H. J. Am. Chem. Soc. **1962**, 27, 3878-3882

- ² Molock, F. F. J. Heterocyclic Chemistry 1983, 20, 681.
- ³ Sezen, B.; Sames, D. J. Am. Chem. Soc. 2003, 125, 5274-5275.
- ⁴ Wang, L.; Chen, Z. C. J. Chem. Res. Synop. 2000, 8, 367-369.
- ⁵ Khan; Polya. J. Chem. Soc. C **1970**, 85-88.
- ⁶ Artico, M.; Silvestri, R.; Stefancich, G.; Avigliano, L.; Di Giulio, A. *Eur. J. Med. Chem. Chim. Ther.* **1992**, *27*, 219-228.
- ⁷ Wang, Li; Chen, Zhen-Chu. J. Chem. Res. Synop. 2000, 8, 367 369.
- ⁸ Du Pont de Nemours, E. I., and Co. "1-(Alkyl-Substituted Phenyl)Imidazoles Useful in ACTH Reserve Assay." US 3637731. 1972.
- ⁹ Du Pont de Nemours, E. I., and Co. "1-Substituted Imidazoles Useful in ACTH
- [Adrenocorticotrophin] Reserve Assay." US 3541109. 1970.

¹⁰ Perry, M. C.; Cui, X.; Powell, M. T.; Hou, D. R.; Reibenspies, J. H.; Burgess, K. J. Am. Chem. Soc. **2003**, *125*, 113-123.

- ¹¹ Tashiro, M.; Itoh, T.; Fukata, G. Synthesis **1982**, 217-219.
- ¹² Paul, R.; Hallett, W. A.; Hanifin, J. W.; Reich, M. F.; Johnson, B. D. J. Med. Chem. **1993**, *36*, 2716-2725.
- ¹³ Liu, J.; Chen, J.; Zhao, J.; Zhao, Y.; Li, L.; Zhang, H. Synthesis 2003, 2661-2666.
- ¹⁴ Pozharskii et al. Chem. Heterocycl. Compd. **1970**. 6, 194-197.
- ¹⁵ Sezen, B.; Sames, D. J. Am. Chem. Soc. **2003**, 125, 10580-10585.
- ¹⁶ Collman, J. P.; Zhong, M.; Zeng, L.; Costanzo, S. J. Org. Chem. **2001**. 66, 1528-1531.